Employers and employees beset by fears over what prescription drug price increases are doing totheir bottom lines and their health have some unexpectedallies.

An asset manager and member of the the Interfaith Center onCorporate Responsibility has submitted drug pricing proposals toMerck & Co. and Gilead Sciences concerning their priceincreases.

Azzad Asset Management, advisor to the Azzad Funds, along withother members of the ICCR, have filed resolutions this year with 11major U.S. pharmaceutical companies and sent letters to anadditional six non-U.S. companies advocating a reasoned and fairreassessment of pricing policy.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.